SIGN IN
Email Address
Password

Intervention & Prevention: Keeping Current with Acute Coronary Syndrome - Journal Club (Issue #11)



This CME Activity has expired and is no longer available for credit. Your test score will not be saved.
To start this activity, click "Begin" at the bottom of this page.

Intervention & Prevention: Keeping Current with Acute Coronary Syndrome - Journal Club (Issue #11)

Release Date:

May 13, 2011

Expiration Date:

May 31, 2012

Topics:

Cardiovascular Diseases
Surgery – Cardiothoracic

Specialty:

Cardiology

Profession:

Physician

Format:

Newsletter

Credits:

2.00 / AMA PRA Category 1 Credit(s)TM


Estimated Time to Complete:

2 hours

Program Description:

Although there have been advances in treatment, the incidence, morbidity, and mortality associated with acute coronary syndrome (ACS) remain significant. Therapy for ACS utilizes a combination of surgical interventions (including percutaneous coronary interventions [PCI]) and pharmacotherapy, with antiplatelet agents playing an essential role. There may be significant risks with these interventions, during the procedure itself and in the months and years following. Ischemic events can continue to occur, despite the use of either standard antiplatelet therapy or variations in dosages and combinations of agents.

Activity Objectives:

After taking part in this educational activity, participants should be better able to:


  • Discuss current approaches to the management of patients with acute coronary syndrome (ACS), particularly those undergoing percutaneous coronary intervention (PCI)

  • Review the current guidelines of the American College of Cardiology/American Heart Association/Society for Cardiovascular Angiography and Interventions regarding use of dual antiplatelet therapy to prevent myocardial infarction (MI) and death in patients following PCI

  • Describe the concept of thienopyridine “resistance,” and explain its potential implications for secondary prevention in patients post-ACS

  • Evaluate emerging options for antiplatelet therapy post-ACS, including new thienopyridines, non-thienopyridines, and other agents, taking into consideration their safety, efficacy, and mechanisms of action.


Credits Type Accreditation Statement Designation Statement
2.00 AMA PRA Category 1 Credit(s)TM This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through joint sponsorship of Albert Einstein College of Medicine of Yeshiva University and Haymarket Medical Education. Albert Einstein College of Medicine of Yeshiva University is accredited by the ACCME to provide continuing medical education for physicians. Albert Einstein College of Medicine of Yeshiva University designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credit(s).TM Physicians should only claim credit commensurate with the extent of their participation in the activity.

Faculty:

PROGRAM CHAIR
James A. de Lemos, MD

Professor of Medicine
Cardiology Division
Southwestern Medical School
UT Southwestern Medical Center
Dallas, TX

PROGRAM FACULTY
Robert P. Giugliano, MD, SM, FACC, FAHA

Senior Investigator, TIMI Study Group
Associate Physician, Cardiovascular Medicine
Brigham and Women’s Hospital
Associate Professor in Medicine
Harvard Medical School
Boston, MA

Anand Rohatgi, MD
Assistant Professor
Division of Cardiology
UT Southwestern Medical Center
Dallas, TX

CME COURSE ADVISOR
E. Scott Monrad, MD

Professor of Clinical Medicine
Albert Einstein College of Medicine
Director, Cardiac Catheterization Laboratory
Einstein Division, Montefiore Medical Center
Bronx, NY

Click to Expand/Collapse Disclosures:

FACULTY DISCLOSURES

James A. de Lemos, MD, has received speakers’ honoraria from sanofi-aventis—Bristol-Myers Squibb partnership; consulting fees from AstraZeneca; and research grants from Roche Diagnostics.

Robert P. Giugliano, MD, SM, has received research support from Daiichi-Sankyo and Merck; and lecture honoraria from Bristol-Myers Squibb, Merck, and sanofi-aventis. He is a consultant for Daiichi-Sankyo, Merck, Ortho-McNeil, Regeneron, sanofi-aventis. Dr. Giugliano is on the data safety monitoring board for Angel Med and on the clinical end point committee for Novo Nordisk.

Anand Rohatgi, MD, has no relevant relationships to disclose.

E. Scott Monrad, MD, has no relevant relationships to disclose.


PUBLISHING STAFF DISCLOSURES

Suzanne Bujara, Melissa Johnson, and Anne Bardsley,
Haymarket Medical Education, have nothing to disclose with regard to commercial support.


DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of approved and/or investigational uses of agents that are not indicated by the FDA. Albert Einstein College of Medicine of Yeshiva University, Daiichi Sankyo, Inc., Lilly USA, LLC, and Haymarket Medical Education do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Albert Einstein College of Medicine of Yeshiva University, Daiichi Sankyo, Inc., Lilly USA, LLC, and Haymarket Medical Education. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


DISCLAIMER

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.


Accredited Provider:

Sponsored by Albert Einstein College of Medicine of Yeshiva University




Commercial Supporter:

Supported by an educational grant from Daiichi Sankyo, Inc., and Lilly USA, LLC.






Produced by Haymarket Medical Education

Instructions:

To obtain credit, a score of 70% or better is required. This CE is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the posttest survey, and have received your digital copy of your credit certificate. Your online certificate will be saved on myCME.com within your Profile/Exam History, which you can then access at any time.

If you have any questions relating to the accreditation of this activity, please contact Mildred Adighiuzor, Associate Director, CME Marketing at (718) 920-6674, ext 231, Albert Einstein College of Medicine, 3301 Bainbridge Avenue, Bronx, NY 10467.

PRIVACY POLICY
To view the myCME privacy policy, please click here.

To view the privacy policy for Albert Einstein College of Medicine of Yeshiva University, please click here.

Click to Expand/Collapse SYSTEM REQUIREMENTS:

WINDOWS PC SYSTEM REQUIREMENTS:
266-MHz Pentium II; Windows 98 or higher; 64 MB RAM; 800 x 600 screen resolution set for “High Color (16-Bit)”; Macromedia Flash Player 6 or higher.

MACINTOSH® SYSTEM REQUIREMENTS:
Power Mac g3 at 300 MHz; System 8.5 or higher (excluding Mac OSX); 96 MB RAM; 20 MB minimum hard disk space available; 800 x 600 screen resolution set to “Thousands of Colors”; Macromedia Flash Player 6 or higher.



Home | Browse By Disease | Browse By Specialty | Browse By Profession | About HME | Contact Us | Web Support

© 2013 Haymarket Media, Inc.

Your use of this website constitutes acceptance of Haymarket Medical Education's Privacy Policy and Terms & Conditions

Haymarket Medical Education